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ABSTRACT
 
Recent advances in genomic re-
search are leading to a new era in 
medicine. In the next few years, the 
use of genomic data in healthcare 
will rapidly increase. In the future, 
decisions regarding the prevention 
and treatment of diseases will be 
increasingly based on an individual’s 
genetic makeup. This major change 
in medicine requires careful prepa-
ration.  
The National Genome Strategy sets 
key measures for ensuring that, by 
2020, genomic data will be effec-
tively used in healthcare and in the 
promotion of health and wellbeing. 
Achieving this objective will require 
development of a Finnish national 
reference database of genomes to 
be used in clinical care and research. 
The capacity of healthcare pro-
fessionals to apply genome-based 
information should be strengthened, 
and people need to be empowered 
to improve their own health by 
effective use of genomic information. 
The working group proposes the 
establishment of a national genome 
centre that would bring together all 
parties within the field of genomics. 
The centre will have the responsibi-
lity for development of the national 
reference database and for imple-
menting many of the actions inclu-
ded in the genome strategy. A legal 
framework should be developed for 
the genome centre, and government 
funding for the centre needs to be 
secured. A strong tradition of genetic 
research in Finland, the existing 
comprehensive health registers and 
population databases, and the high 
quality sample collections in biobanks 
are valuable assets that provide a 
solid basis for implementing the pro-
posed actions. 
Finland has the potential to grow into 
an internationally interesting partner 
in genomics research and geno mics-
related enterprise. This objective can 
be achieved through closer coope-
ration between the relevant stake-
holders in Finland and by entrusting 
the national genome centre with the 
negotiation of contracts on behalf of 
the Finnish partnership network. A 
national service point at the genome 
centre would enhance genomics 
research and innovation, benefiting 
directly both Finns and Finland’s 
health services. However, the window 
of opportunity for exploiting Finland’s 
strengths will be open for a few years 
at best.
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TIIVISTELMÄ
Perimän tutkimuksessa saavutetut 
edistysaskeleet johtavat uuteen 
aikakauteen lääketieteessä. Genomi-
tiedon eli ihmisen koko perimästä 
saatavan tiedon käyttö terveyden-
huollossa yleistyy lähivuosina. Tulevai-
suudessa terveyden edistäminen ja 
sairauksien hoito suunnitellaan usein 
yksilöllisesti perimästä saatavan tie-
don perusteella. Tähän muutokseen 
on valmistauduttava huolella.
Kansallisessa genomistrategiassa esi-
tetään keskeiset toimenpiteet, joilla 
varmistetaan genomitiedon tehokas 
hyödyntäminen terveydenhuol-
lossa sekä terveyttä ja hyvinvointia 
edistävässä päätöksenteossa vuonna 
2020. Tavoitteeseen pääseminen 
edellyttää kansallisen genomitieto-
kannan perustamista ja tietokannan 
hyödyntämistä potilaiden hoidossa 
ja tieteellisessä tutkimuksessa. Lisäksi 
on vahvistettava terveydenhuollon 
ammattilaisten valmiuksia käyttää 
genomitietoa sekä ihmisten kykyä 
tehdä terveyteensä liittyviä päätöksiä. 
Työryhmä esittää kansallisen, kaikki 
toimijat yhdistävän genomikeskuk-
sen perustamista. Sen tehtävänä on 
vastata valtakunnallisen genomitie-
tokannan kehittämisestä ja usei-
den genomistrategiaan sisältyvien 
toimenpiteiden toimeenpanosta. 
Genomikeskuksen perustamisesta 
olisi säädettävä lailla ja sen kansal-
linen rahoitus olisi varmistettava. 
Suomen vankka osaaminen geenitut-
kimuksessa, kattavat terveystietojen 
tietovarannot ja biopankkien korkea-
laatuiset näytekokoelmat muodosta-
vat huomattavan kansallisen pää-
oman, johon perustuen ehdotetut 
toimenpiteet voidaan toteuttaa. 
Suomella on kaikki edellytykset 
nousta kansainvälisesti tavoitelluksi 
yhteistyökumppaniksi genomi-
tutkimuksessa ja genomiikka-alan 
yritystoiminnassa. Tämä tavoite 
saavutetaan tiivistämällä toimijaken-
tän yhteistyötä ja antamalla genomi-
keskukselle valtuudet valmistella 
keskitetysti sopimuksia suomalai-
sen yhteistyöverkoston puolesta. 
Kansallisen palvelupisteen luomi-
nen genomikeskukseen tehostaisi 
suuresti genomitutkimusta ja alan 
kehitystoimintaa, joiden tulokset 
hyödyttäisivät suoraan suomalaisia ja 
suomalaista terveydenhuoltoa.
Aikailuun ei kuitenkaan ole syytä. 
Aikaikkuna Suomen vahvuuksien 
hyödyntämiselle on korkeintaan 
muutama vuosi.
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SAMMANDRAG
Framstegen inom genomforskningen 
håller på att inleda en ny tidsera 
inom medicinen. Användningen av 
genominformation, dvs. information 
om människans hela arvsmassa, 
kommer under de närmaste åren 
att öka inom hälso- och sjukvården. 
I framtiden kommer hälsofrämjan-
de och vård av sjukdomar ofta att 
planeras individuellt utifrån den 
information som fås från genomet. 
Den här förändringen måste man 
omsorgsfullt förbereda sig inför.
I den nationella genomstrategin fö-
reslås centrala åtgärder genom vilka 
det kan säkerställas att man i Finland 
år 2020 effektivt använder genomin-
formation till godo för människor-
nas hälsa inom hälsovården och i 
beslutsfattande som främjar hälsa 
och välmående. För att målet ska 
uppnås krävs det att det inrättas en 
nationell genomdatabas som det är 
möjligt att utnyttja i vården av pa-
tienter och i vetenskaplig forskning. 
Det kunnande som yrkespersoner 
inom hälso- och sjukvården har att 
använda genominformation och den 
förmåga som människor har att fatta 
beslut som berör den egna hälsan 
behöver stärkas. 
Arbetsgruppen föreslår att det 
inrättas ett nationellt genomcentrum 
som förenar alla aktörer och som 
ska svara för utvecklandet av den 
nationella genomdatabasen och ge-
nomförandet av flera av de åtgärder 
som ingår i genomstrategin. Försla-
get innebär att det föreskrivs genom 
lag om inrättande av ett genomcen-
trum och att den nationella finansie-
ringen säkerställs. Finlands gedigna 
kunnande inom den genetiska forsk-
ningen, de heltäckande datalagren 
för hälsodata och de högkvalitativa 
provsamlingarna i biobankerna bildar 
ett betydande nationellt kapital som 
genomförandet av de föreslagna 
åtgärderna kan grundas på. 
Finland har alla förutsättningar för 
att bli en internationellt eftertraktad 
samarbetspartner inom genomforsk-
ning och företagsverksamhet inom 
genomikbranschen. Detta mål kan 
uppnås genom ett tätare samarbe-
te mellan de olika aktörerna och 
genom att genominstitutet ges be-
fogenheter att centralt bereda avtal 
på det finska samarbetsnätverkets 
vägnar. Inrättande av ett nationellt 
serviceställe vid genomcentrum-
et skulle i stor grad effektivisera 
genomforskningen och utvecklandet 
av branschen, och resultaten av 
denna verksamhet kunde komma 
till direkt nytta för finländarna och 
den finländska hälso- och sjukvården. 
Tidsramen för utnyttjandet av Fin-
lands styrkor är dock högst några år.
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FOREWORD
Within the next few years, recent 
advances in genomics technology 
will enable wide-ranging use of 
genomic data in clinical care and in 
the prevention of diseases. Com-
prehensive planning is required to 
prepare for this change. The devel-
opment of such a plan was included 
in the recommendations of the 
national Strategy for Growth in Re-
search and Innovation in the Health 
Sector, published in May 2014 (MEE 
reports 12/2014). 
The Ministry of Social Affairs and 
Health (MSAH) set up a working 
group to formulate a National 
Genome Strategy in healthcare 
during the period of 1.9.2014 – 
30.4.2015. The strategy will establish 
the conditions that are required for 
the effective utilisation of genomic 
data in Finnish healthcare. It will also 
promote genomics research and 
the development of applications for 
genomic data in the field of human 
health.
The Chair of the working group was 
Director Liisa-Maria Voipio-Pulkki 
from MSAH’s Department for 
Social and Health Services, and the 
Vice-Chair was Professor Kristiina 
Aittomäki from the University of 
Helsinki and the Hospital District of 
Helsinki and Uusimaa’s laboratory 
service (HUSLAB). The members of 
the working group are presented in 
Appendix 2.
 
In the formulation of the strategy, 
the Ministry of Social Affairs and 
Health worked closely with the 
Finnish Innovation Fund Sitra. The 
Health Section of the Advisory 
Board on Biotechnology acted as a 
consultative expert group. 
During the autumn of 2014, the 
working group organised six 
workshops on different themes. 
More than one hundred experts 
from various fields participated, as 
did representatives of other stake-
holder groups such as companies. 
The working group used the views 
presented during the workshops to 
draft strategic goals and proposals 
for an action plan. The stakeholders 
gave their feedback on the propos-
als during a hearing and discussion 
held on January 12, 2015. The ex-
perts and anyone else interested in 
the subject were given the oppor-
tunity to comment on the proposals 
and the draft strategy through the 
Innovillage collaborative develop-
ment platform and the “otakantaa.fi ” 
service which enables people to ex-
press their views on public decisions. 
The feedback was taken into consid-
eration when finalising the strategy. 
During the development of the 
strategy, an active public communi-
cations programme on the progress 
of the work was maintained. 
Having completed its work, the 
working group respectfully sub-
mits its unanimous proposal for a 
National Genome Strategy to the 
Ministry of Social Affairs and Health. 
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1. INTRODUCTION
The novel research methods in genetics open up new possibilities to identify the causes of human health and 
disease, as well as to create new means for disease prevention and targeted care. The use of genomic data, i.e. 
information about an individual’s whole genetic makeup, is rapidly increasing in healthcare. In the future, health 
promotion and the treatment of diseases will be increasingly based on individual genetic makeup. Genomic data 
will enable us to make better individualised choices, to target the screening of the diseases more precisely, to 
make more accurate diagnosis and to select the most effective care. 
WHAT IS KNOWN 
ABOUT A PERSON’S 
GENETIC MAKEUP?
Human genetic makeup or genome 
has been researched for decades in 
order to diagnose diseases and to 
understand their causes. There was 
a significant step forward in genome 
research in 2000, when the full se-
quence of the human genome was 
completed. Although not perfect, it 
launched a technological develop-
ment producing a range of methods 
which could be applied to genome 
research and were significantly more 
cost-effective than before. 
The new genomic methods, i.e. 
methods that examine the entire 
genetic makeup of a person instead 
of individual genes, expand the use 
of genetic information to cover hu-
man health, susceptibility to diseases, 
and changes in the genetic makeup 
that are linked to a specific disease. 
Above all, we have seen the high 
level of variation in people’s genet-
ic makeup, and understood that 
individual differences in susceptibil-
ity to many common diseases are 
related to this variation. Thus we can 
presume that preventive methods 
and individual treatments can also 
be developed for the most common 
diseases. These methods would be 
applied especially in high risk groups. 
SIGNIFICANCE OF GENOMIC 
DATA TO THE INDIVIDUAL 
AND THE SOCIETY
Data on individual genetic makeup is 
a key to promoting health and well-
being as well as new thinking about 
healthcare and practices. Extensive 
use of genomic data is expected to 
produce significant benefits 
(Figure 1).  Individuals will be able 
to get more effective medicines and 
care. It will be possible to diag-
nose diseases at an early stage and 
more accurately. In addition, we can 
identify individual risks of disease 
and prevent diseases before their 
onset. The use of genetic informa-
tion will also enable people to take 
Practical applications of 
genomic data
Cost-effective drug treatment 
with pharmacogenomic tests
Clopidogrel is a commonly used drug to 
prevent clotting in the blood vessels of 
the heart and brain. Every year about 
30,000 new patients are prescribed this 
medication in Finland. For about 15-25% 
of patients the prevention of vascular 
events is low because the genetic 
changes in the CYP2C19 enzyme slow 
down the production of the active drug 
in their bodies. Therefore, in order to 
evaluate the effectiveness of the drug 
treatment, a CYP2C19 genetic test 
should be carried out on patients before 
prescribing clopidogrel. 
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responsibility for their own health 
and wellbeing, should they so wish. 
Since the new technologies have 
significantly reduced the cost of se-
quencing the genome, various types 
of genetic tests are being offered 
also direct-to-consumer around the 
world. These technologies enable 
anyone to obtain information on his 
or her own genetic makeup. The ob-
jective of the genome strategy is to 
create equal opportunities to health 
benefits brought by genomic data. 
Combining information on genetic 
makeup with health data will con-
tinuously generate new information 
about the relationship of genetic 
makeup to diseases and the results 
of their treatments. This information 
will benefit and save the costs of 
healthcare, as interventions can be 
designed to be more preventive and 
cost-effective 
If Finland succeeds in building an 
interesting research and business en-
vironment in the field of genomics, 
this could generate significant new 
scientific and commercial activities 
for Finland. Research will benefit 
from improved availability of genom-
ic data, and commercial activities will 
have a point of contact for building 
up innovation and business around 
genomic data.
The systematic collection of genetic 
information has increased rapidly 
in several countries during recent 
years. In order for genetic infor-
mation to be more widely used in 
healthcare, clinical research and in 
commercial applications, people 
should have confidence that their 
genetic information is used in an 
ethically responsible and legally 
sound manner. Genomic data are 
sensitive personal data. Therefore 
data protection regulations will have 
to be taken into consideration in the 
implementation of the strategy. Par-
ticular attention should be paid to 
the secure use of genomic data and 
the maintenance of people’s trust.
Practical applications of genomic data
Prevention and targeted treatment of diabetes
Diabetes (DM) is one of the fastest growing diseases in Finland and the world. 
Over 500,000 Finns suffer from diabetes, and it is estimated that the number of patients 
could double during the next 10−15 years.
The spectrum of diabetes is complex. Molecular genetic research has also identified 
rare hereditary forms. There are over one hundred known genetic changes increasing 
predisposition to the most common form, type 2 diabetes, but there could be thousands 
of these changes in the genome. Therefore people belonging to genetic risk groups have 
a large number of modifications in their genetic makeup that make them susceptible to 
diabetes. 
If each year 2-5% of diabetes cases could be prevented by risk profiling and 
preventive action, the direct savings in health care costs would be 28–70 million euros 
a year including the additional costs caused by co-morbidities of DM. In addition, more 
accurate identification of the sub-type of diabetes would help to predict the course of the 
disease in each patient and to select targeted treatment.
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Increased 
wellbeing
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Safer 
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screening
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their own health
Personalised 
treatment
Figure 1.  The benefits of using genomic data effectively. 
BENEFITS OF USING GENOMIC DATA EFFECTIVELY
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Practical applications of genomic data
Genetic test reduces morbidity and mortality
Lynch syndrome is a hereditary condition causing susceptibility to cancer. It has a high risk 
of colon cancer, and uterine and ovarian cancer in women. The child of a carrier of the 
genetic defect has a 50% risk of inheriting the defect. All carriers of the genetic defect 
are monitored regularly by colonoscopy. Those who have not inherited the genetic defect 
do not need follow-up. 
Through follow-up of the carriers of the defect, over 50% of the colon cancer cases can 
be prevented by removing the precancerous lesions during colonoscopy. The prognosis of 
confirmed cancer is generally good since they are detected at an early stage. Therefore 
genetic tests are cost-effective and reduce both morbidity and mortality caused by Lynch 
syndrome.
GENOMIC TECHNOLOGY 
IS TRANSFORMING 
HEALTHCARE
Genetic tests are already fairly wide-
ly used in healthcare. In 2012, 
approximately 100,000 genetic 
tests were carried out in Finland. Of 
these, about 30% were carried out 
to diagnose hereditary diseases and 
to identify high susceptibility to 
certain diseases. In the future, there 
will be no radical change in the 
status of these genetic tests, but 
they will become more comprehen-
sive and more cost-effective.
The application in healthcare of 
information gained from genome 
research is becoming significantly 
more diverse. Depending on their 
purpose, genome-wide tests can be 
divided into the following groups: 
1)  Diagnostic tests for defining 
the cause of a rare disease or for 
identifying high-risk susceptibility for 
a specific disease
2)  Research into the molecular 
mechanisms of diseases. For ex-
ample, examination of the genetic 
changes in a malignant tumour as a 
part of cancer treatment  
3)  Pharmacogenetic tests for the 
assessment of the suitability of a 
specific drug for a patient’s treat-
ment 
4)  Predicting susceptibility to 
common diseases by genetic risk 
profiling. 
This kind of use of genomic data 
produces peronalized healthcare. It 
predicts risks, prevents diseases and 
is both customized and participatory. 
Participatory means that a person 
is more capable of taking care of his 
or her health by having access to 
comprehensive information on the 
factors affecting it.
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2. FINLAND AS A UTILIZER OF GENOMIC DATA
The genetic structure of the Finnish population provides us with a unique possibility to function as pathfinders 
and early utilizers of genomic data. By combining genomic and health data we can identify connections of genetic 
makeup to the health of the population and the effectiveness of treatment in a manner which would be difficult 
or impossible elsewhere. Finland is also one of the world’s leading developers of health technology and experts 
in information and communications technology. Finland has an opportunity to become a model country in com-
bining genetic information, clinical data and information on personal wellbeing. 
INTERNATIONAL 
OPERATING ENVIRONMENT
The opportunities for utilizing 
genomic data in medicine have 
been recognised around the world. 
Several countries have drawn up, or 
are drawing up, strategies and action 
plans to utilize genomic data.
For example, the British National 
Health Service (NHS) has launched 
a 300 million pound genome project 
with the target of reading the ge-
netic makeup of 100,000 people. In 
Germany, the Ministry of Education 
and Research has earmarked 360 
million euros to promote personal-
ized medicine during the next three 
years. And in the United States, a 215 
million dollar genome project has 
been launched. All these projects aim 
at utilizing the results in the health-
care sector. At the same time they 
generate data which can be used in 
developing new medicines and 
methods for early detection and 
treatment of diseases. 
Also Estonia has advanced in the 
collection and utilisation of genomic 
data. The legislation on research into 
human genes was passed in 1999, 
and one year later Estonia’s genome 
project fund was established. In 
Estonia, there is a specific objective 
to reduce the costs of healthcare by 
investing in the use of genomic data 
in the prevention of disease. 
NHS compares the genome project 
with the construction of railways 
during the Victorian era. The railway 
did not just provide a fast and 
cheap way of moving from one 
place to another, but also increased 
commercial activity in many ways. 
The genome project is expected to 
promote innovation and economic 
activity within the health sector, 
which will contribute to creating 
welfare in the country.
Several other countries, such as Italy 
and Canada, have launched projects 
aiming at utilizing genomic data with 
the objective of improving national 
health care systems and making 
them more efficient. On the other 
hand, this can also be seen as a part 
of worldwide research and business. 
Nations that are the first to attract 
international partners will gain the 
most benefit from cooperation. 
FINLAND COULD BECOME A 
MODEL OF GENOMIC DATA 
USE
Finland is particularly well placed to 
utilize genomic data. From a global 
perspective, Finland’s strengths in-
clude a high standard of healthcare, 
uniform treatment practices, reliable 
healthcare registers, a long tradition 
of high-quality genetic research, and 
the willingness of the population to 
participate in scientific research. 
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Finns are genetically relatively 
homogenous. This provides special 
opportunities to combine genomic 
and health data. As a result, genetic 
mechanisms targeted by drugs can 
be identified in a manner that is 
difficult, if not impossible, elsewhere. 
Finland is also one of the world’s 
leading developers of health tech-
nology. In addition, we have good 
skills in information and communica-
tions technology. In the future, it will 
be possible for individuals to collect 
information relating to their health 
and lifestyle using the My Kanta Pag-
es service that is part of the national 
health data repository. 
The ability of the Finnish healthcare 
system to utilize the new possibilities 
offered by genomic data depends 
on current information technology 
solutions and on the training of 
healthcare professionals to utilize 
genomic data. 
There are already significant projects 
and programmes supporting the 
utilisation of genomic data in the 
Finnish healthcare. For example, the 
objective of the GeneRISK Study 
is to analyse how the provision 
of information about one’s health 
and possible risk factors motivates 
people to change their lifestyles 
and prevent diseases. If 2 to 5 per 
cent of heart and vascular diseases 
could be prevented, this would save 
healthcare costs of 10–26 million 
euros every year. 
THREATS AND RISKS 
RELATED TO UTILISATION 
OF GENOMIC DATA
Everyone must have an equal 
opportunity to benefit from 
genomic data. If Finland is not well 
prepared to make use of this data, 
the development of healthcare in a 
more preventive and cost-effective 
direction may be undermined. In this 
case, genomic data would benefit 
mainly those who can acquire and 
utilise it on their own initiative. 
A critical requirement for the 
collection and utilisation of genomic 
data is that people can trust it to be 
handled confidentially with sufficient 
security measures respecting their 
wishes and rights. Lack of legislation 
or clarity and conflicting interpre-
tations could limit the utilisation of 
genomic data. In order to ensure 
that the data are not used against 
the wishes of the person or with-
out their consent, and that all the 
measures are carried out according 
to the law, ethical and legal guide-
lines as well as interfaces with data 
security must be created. 
There is a risk that the operating en-
vironment becomes fragmented and 
that there will be several different 
databases for storing genomic data. 
This would be particularly damaging 
to Finland, given its comparatively 
small population. There is also a risk 
that no new economic activity will 
be generated around genomic data 
research in Finland. In that case, 
potential international partners will 
focus their interest elsewhere. 
New information technology 
solutions help people to use their 
own genetic information safely. We 
must ensure that genomic data are 
generated and processed only by 
organisations that have the necessary 
professional and scientific resources 
and methodologies. Surveys and 
interviews should be carried out 
at regular intervals to ensure that 
the use of genetic information is in 
accordance with the needs, expecta-
tions and concerns of the population. 
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DNA chips provide a rapid method 
to analyze hundreds of thousands 
of genetic changes simultaneously.
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3. GOALS OF THE GENOME STRATEGY 
Due to the rapid increase in genomic data, there is a need for a National Genome Strategy. This would enable 
healthcare to pave the way for the effective use of genomic data without compromising the legal protection and 
fair treatment of individuals. At the same time, we need to ensure that Finland becomes an attractive country 
for top level international research and innovation utilizing genomic data. A national genome centre is needed to 
implement the genome strategy, to coordinate cooperation and to ensure that the strategic goals are achieved.
NEED FOR A GENOME 
STRATEGY
The full-scale use of genomic data in 
healthcare requires thorough prepa-
ration. There is a need for a com-
prehensive strategy to respond to 
the many challenges. These include 
health technology assessment of ge-
netic tests; quality assurance of the 
genetic tests and testing laboratories; 
equity in access to genetic testing 
and counselling as well as treatment 
based on the test results; training 
of healthcare staff; data protection; 
dealing with incidental findings; and 
containing the costs of genetic tests 
and personalized care. 
STRATEGIC AIM
The aim of the strategy is to make 
Finnish healthcare more effective. 
This will be achieved by providing 
people with better and more target-
ed care. Healthcare professionals will 
gain access to more comprehensive 
genomic data for application in clin-
ical care. Researchers, for their part, 
will have entirely new opportunities 
for utilizing genomic data in scientific 
research. Society may benefit from 
a containment of healthcare costs 
and better allocation of resources. 
In addition, the aim is to transform 
Finland into an internationally attrac-
tive environment for research and 
business in the field of genomics.
IMPROVING HEALTH 
THROUGH THE USE OF 
GENOMIC DATA
The strategic vision is: 
         
         In 2020, genomic infor-
mation will be effectively used 
in Finland to achieve popula-
tion health benefits”. The guid-
ing principle of the strategy is 
“Improving health through the 
use of genomic data. 
The strategy is limited in scope to 
the promotion of human health and 
wellbeing. It does not address other 
significant spheres of application of 
genomics nor specific treatments. 
The aim is to implement the strate-
gy by 2020. 
The genome strategy is aligned with 
the Health Sector Growth Strategy 
for Research and Innovation Activ-
ities and the national eHealth and 
eSocial Strategy. The implementa-
tion of the genome strategy should 
rely as far as possible on existing 
structures. 
A particular focus of the strategy 
is on data utilisation. The aim is 
that Finland would concentrate on 
using genomic data to produce high 
added value. Another area of focus 
is creating a single body, a genome 
centre, for the management of 
genomic data and to serve as a na-
tional service point for stakeholder 
groups using genomic data. 
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ULTIMATE GOALS
Use of genomic 
data is governed 
by ethical 
principles and 
legislation 
Genomics research 
is closely 
integrated into 
healthcare
Healthcare 
personnel have 
skills to use 
genomic data
Information 
systems enable 
effective use of 
genomic data
Genomic data 
are widely used 
in healthcare 
based on 
individual and 
population 
needs
Individuals
are able to 
make use of 
genomic data 
in their own lives
Finland is 
an attractive 
research and 
business 
environment 
in genomics
Figure 2.  The goals of the genome strategy.
ENABLING GOALS
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STRATEGIC GOALS
The genome strategy has seven 
main goals, four of which are ena-
bling goals and three are ultimate 
goals (Figure 2). 
By achieving the enabling goals, 
the necessary conditions will be 
created for the full-scale use of 
genomic data in healthcare, 
research and commercial activity as 
well as in people’s own lives. 
The enabling goals are related to 
ethical principles and legislation, 
the integration of genomic 
research into healthcare, the ability 
of healthcare professionals to apply 
genomic data, and the development 
of information systems that will 
enable the efficient utilisation 
of the data. 
The ultimate goals are built on the 
foundation of the enabling goals. The 
actual benefits of genomic data use 
for individuals, Finnish healthcare and 
the society will be obtained through 
the attainment of the ultimate goals.
A national genome centre is needed 
for the implementation of the ge-
nome strategy. The genome centre 
will develop and maintain a national 
reference database of genomes and 
a database of genomic variants. It 
will provide a single point of contact 
for research institutions and com-
panies needing research, contractual 
and commercialisation services.
In the following chapters, each 
goal and the proposed activities to 
achieve them are described.
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3.1 ETHICAL PRINCIPLES AND LEGISLATION GOVERN 
THE RESPONSIBLE USE OF GENOMIC DATA
Advances in genomic technology raise ethical and legal issues relating to people’s privacy and the predictive na-
ture of genomic data, among other things. In order for genomic data to be used effectively in healthcare, research 
and in commercial activities, the use of data related to the human genome must be safe and governed by law and 
guidelines.
Genetic tests generate data on the 
genetic makeup of both the individ-
ual and his or her biological relatives. 
The data can be used to predict 
disease by identifying whether the 
person has a genetic change that will 
cause a disease or protect the per-
son from it. It is important that peo-
ple get enough information about 
the significance of genomic data. 
Because of the sensitive nature of 
information about a person’s genetic 
makeup, it is necessary to ensure 
that the data are not used in a 
way that would harm that person 
or other people. Everyone should 
have the right to manage one’s own 
genomic data. New information 
technology solutions make it easier 
for people to monitor and use their 
genomic data. This has to be en-
sured through legislation. Everyone 
can decide for themselves whether 
they wish to be informed about 
their genetic makeup and suscepti-
bility to diseases. Everyone should 
also be given the opportunity to re-
ceive counselling on the implications 
of the findings of genetic tests.
The interests and welfare of the 
individual should always have pri-
ority when investigating the human 
genome. Discrimination based on 
genetic makeup is prohibited in 
many international agreements, 
declarations and recommendations 
to which Finland is committed. The 
Council of Europe’s Convention 
on Human Rights and Biomedicine 
allows predictive genetic testing 
for health purposes only, or for 
health-related scientific research. 
Thus genetic tests cannot be carried 
out, for example, for insurance 
purposes. Finland’s criminal code 
prohibits discrimination in employ-
ment on the grounds of genetic 
characteristics. 
The use of genomic data involves 
the handling of sensitive personal 
data. Consequently, data protection 
regulations will have to be taken 
into account in the implementation 
of the strategy. 
Information systems must be de-
veloped so that genomic data are 
stored and used securely. Privacy 
must be protected and misuse 
of information about an individu-
al’s genetic makeup prevented. In 
the case of data about a person’s 
entire genetic makeup, conventional 
precautionary measures cannot 
completely eliminate the possibil-
ity of the person being identified. 
Therefore genetic data linked to an 
identifiable person and stored for 
scientific research or any other pur-
poses must be held confidential.
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ACTIVITY 1 
– Confirm the ethical principles 
concerning the use of genomic 
data
Establish a multi-disciplinary working 
group to draw up ethical principles 
and working practices which respect 
the rights of the individual and for 
the responsible use of genomic 
data in healthcare, research and 
product development. International 
recommendations should be taken 
into account when drawing up the 
principles. Promote the adoption of 
these principles and working practic-
es through training. 
ACTIVITY 2 
– Prepare legal framework for 
the use of genomic data
The needs for revision of the legisla-
tion are identified and the necessary 
regulatory amendments are pre-
pared. 
The applicable data protection regu-
lations are mapped out, and the pur-
pose of collecting and using genomic 
data, among others, is defined.  
19
3.2 GENOMICS RESEARCH 
IS CLOSELY INTEGRATED INTO HEALTHCARE 
The Finnish public healthcare system has broad responsibility for the citizen’s health.This has enabled to establish 
large databases related to healthcare. This data together with genomic information, other public registers and 
our specific population history, create exceptionally good conditions for the use of genomic data in research and 
healthcare.
Valuable sample collections have 
been put together in Finland, such 
as the National Institute for Health 
and Welfare’s population research 
material that has been collected over 
decades. A large part of the sample 
collections is being transferred to 
wider use under the terms of the 
Biobank Act. These collections of 
samples and the possibility to com-
bine them with register data have 
placed Finland, like other Nordic 
countries, in the position of being an 
internationally interesting centre for 
genome research. 
Even on a global scale, Finland’s 
national registers provide a rare 
opportunity to link collected samples 
to long-term monitoring data. This 
increases the value of the collections 
considerably. The goal is that in the 
future, all patient data and national 
register data can be combined with 
genomic data. 
For scientific research and health-
care there is a need not only for 
international reference databases 
but also data about the genome of 
the Finnish people and its variations. 
Finns relate positively to scientific 
research. As a result, the collection of 
samples needed to create a referen-
ce database can be carried out as 
part of healthcare visits. 
ACTIVITY 3 
– Create a national 
reference database of 
genomes
A national reference database 
of genomes will be established. 
Genomic data produced by various 
organisations will be stored in the 
database, and the linking of health 
data with genomic data will be made 
possible. In addition, the necessa-
ry links to international databases 
should be set up.
Plan and implement the collection 
and management of the consents 
required for the use of genomic data. 
Consent can be given during a health-
care visit, taking into account the 
individual’s informed right to decide. 
ACTIVITY 4 
– Identify the procedures and 
create the conditions for using 
scientific data effectively and 
efficiently in healthcare 
Subject to authorisation, it has been 
possible to use healthcare data 
in scientific research that utilises 
genomic data. The transfer of genomic 
data in the opposite direction, from 
scientific research to patient care 
has been considerably less common. 
However, high quality genomic data 
generated in research would be 
useful, for example, in the selection 
of certain drug treatments. In addi-
tion, procedures should be created 
to evaluate which incidental findings 
revealed by research should be com-
municated to people and how. 
 
The long-term goal is to use referen-
ce databases in planning healthcare 
services and in targeting them at 
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the population and individual level. 
In addition, it must be ensured that 
healthcare units have the right to 
access data in order to promote 
appropriate and cost-effective care. 
The unit providing care should have 
at their disposal all available, relevant 
information.
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3.3 HEATHCARE PROFESSIONALS HAVE 
THE KNOWLEDGE AND SKILLS TO USE GENOMIC DATA
In the future, primary and specialised care providers must have knowledge of genomics and skills to apply genom-
ic information in service planning and clinical care. The need for genetics services is increasing. Fair access to 
services can only be ensured through adequate training of healthcare personnel. 
The education and training of 
healthcare professionals must be 
developed to ensure that the 
personnel has up-to-date knowled-
ge and skills in genomics and on 
the use of genetic information and 
its limits. The personnel needs to 
know where they can access new 
information related to genomics and 
how genetic tests and information 
can be used in healthcare. Training in 
the use of genomic data should be 
tailored for each professional and 
specialist group. Training curricula 
must be updated regularly. 
ACTIVITY 5 
– Reinforce and update genetics 
education in the curricula of 
healthcare professionals
Enhance genetics education by 
mainstreaming it in the initial pro-
fessional education of doctors and 
other healthcare professionals. The 
goal is that during basic training the 
student acquires adequate knowled-
ge about genetics and the use of 
genetic information. 
ACTIVITY 6 
– Develop and implement a 
training programme for the 
current healthcare workforce
Develop a training programme on 
genomics for the continuing pro-
fessional development of different 
groups of healthcare professionals. 
The programme should be versatile 
and utilize online training.
ACTIVITY 7 
– Assess the need for profes-
sionals in clinical genetics
In Finnish healthcare, the genetics 
professionals working in the clinical 
setting are doctors specialised in 
genetics and genetics nurses who 
have been trained on the job. In 
many countries, there is also a third 
category of health professionals, ge-
netic counsellors, who are trained in 
genetic counselling. The need for all 
three professional groups in Finland 
should be assessed and the number 
of trainees should be adjusted based 
on identified needs. If necessary, a 
curriculum for genetic counsellors 
should be introduced. 
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3.4 FINLAND HAS INFORMATION SYSTEMS ENABLING 
THE EFFECTIVE USE OF GENOMIC DATA
The extensive use of genomic data requires seamless data connections across information systems and interfaces. 
Finland must develop a comprehensive IT architecture for managing genomic data.
Historically, the emphasis in the 
development of information systems 
in the health sector has been on 
the collection and local utilisation of 
data within organisations. As a result, 
data transfer between organisations 
is not seamless at the moment. 
The national eHealth and eSocial 
Strategy shifts the emphasis of de-
velopment work from collecting and 
transferring data to ways of using 
data efficiently in the promotion of 
personal wellbeing, in the clinical set-
ting and in healthcare management. 
The objective is also to use the data 
to support research, innovation and 
commercial activities.
The special features of genomic 
data are the large size of storage 
required, the need for a national 
reference database and the wide 
range of applications of genomic 
data in different areas and levels 
of healthcare. For the utilization of 
genomic data it is important that the 
information technology solutions are 
implemented using open and secure 
interfaces. 
The utilisation of genomic data 
should not be seen simply as an 
information technology project, but 
as part of the development of an 
ecosystem for public and private 
services. In the future, various kinds 
of services and applications can 
be built around genomic data. For 
example, there will be a need for 
more genomic data interpretation 
services. Even if an individual’s 
genome does not change, it will be 
interpreted several times either as 
a whole or in part as understanding 
of the influence of genomic data 
increases. Interpretation of this data 
requires a broad base of compari-
son material (reference and variati-
on databases).
The informatics requirements for 
the use of genomic data should be 
taken into account in the deve-
lopment of national IT solutions 
in order to avoid creating double 
structures. 
In addition to national solutions, it 
is extremely important to adhere 
to international standards. This will 
ensure that genomic data produced 
in Finland are internationally com-
parable.
 
The efficient use of genomic data 
will bring significant benefits to heal-
thcare and research. The greatest 
benefit is gained when genomic data 
are combined with other healthca-
re and wellbeing information such 
as clinical patient data as well as 
information about lifestyle and en-
vironment. Existing solutions will be 
heavily relied on for the collection, 
storage, combining and utilizing the 
data. In addition, a service operator 
enabling the efficient use of data is 
being planned. It will play an impor-
tant role in the processing of data 
for scientific and other purposes 
(Figure 3). 
There are several electronic ser-
vices in Finland that people are 
familiar with and value. These could 
be used more widely in healthcare. 
New information needs should be 
kept in mind when developing data 
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DATA UTILISATION
Figure 3.  High-level design of the architecture for the generation, storage, 
processing and utilisation of genomic data. 
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management systems. For instance, 
in the future information about an 
individual’s genetic makeup could be 
included in decision support tools 
and other self-treatment services 
used by individuals. People must 
have the right to manage, prevent or 
limit the utilisation of their genomic 
and health data. On the other hand, 
there must also be a possibility to 
provide, subject to the individual’s 
consent, anonymous data to com-
mercial operators, for example to 
be utilized in the development of 
new medicines.
This component of the genome 
strategy focussing on information 
technology will be implemented 
jointly with the national eHealth 
and eSocial Strategy. During imple-
mentation, the genome strategy will 
capitalise on the results of other 
ongoing Finnish projects that are 
related to the genome strategy 
such as the Finnish Innovation Fund 
Sitra’s service operator project and 
research projects coordinated by 
the Institute for Molecular Medicine 
Finland (FIMM), the Finnish Funding 
Agency for Innovation (Tekes) and 
SalWe Ltd.
ACTIVITY 8 
– Develop an IT architecture 
for genomic data
Define the aims for utilizing genomic 
data, especially with regard to ope-
rational needs. Identify the national 
and international standards and 
conceptual models to be followed 
in storing, transferring and utilizing 
genomic data. One of the first tasks 
is to decide on a common data 
storage format. This will ensure that 
the data are stored in a structured 
manner and that data generated 
using different definitions can be 
utilized in a reliable way.
The building of a comprehensive 
structure will also include developing 
national guidelines on data security 
and protection as well as on the ma-
nagement of consents and refusals. 
There will also be a public platform 
for the storage and utilisation of 
genomic data where people can ma-
nage and control their own health 
information in order to promote 
their personal wellbeing. 
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3.5 GENOMIC DATA ARE WIDELY USED IN HEALTHCARE 
BASED ON INDIVIDUAL AND POPULATION NEEDS
The use of genomic data can improve diagnosis and enhance the targeting of treatment. With genetic risk profil-
ing, screening can be focussed more precisely on susceptible subgroups of the population. The efficient utilisation 
of genomic data must be equally available to the entire population. In addition, empowering people to use their 
own genetic information as an aid in health planning will contribute to the prevention of diseases and enable 
many to live a healthier life.
ACTIVITY 9 
– Ensure that sufficient genetic 
testing is performed on pa-
tients to determine the cause 
of diseases, and that test results 
also benefit family members 
and other relatives
Genetic tests for inherited diseases 
and high-risk susceptibility will be-
come increasingly important. In the 
future, decisions regarding treatment 
and monitoring will be based to a 
greater extent on information on 
the location of mutations in genes 
and the type of mutations. Identifi-
cation of family-specific mutations 
is essential for identifying risk of 
disease or for ruling it out in family 
members and relatives. It will also 
result in a more efficient alloca tion 
of resources. It is important to 
ensure equitable access to genetic 
testing in the Finnish healthcare 
system. Genetic tests are particu-
larly valuable in the investigation 
of inherited diseases and high-risk 
susceptibility in situations where the 
test results have relevance to several 
family members. 
ACTIVITY 10 
– Develop a procedure for 
the systematic evaluation and 
adoption of genetic tests 
As genomic data changes, it is 
impossible for every healthcare 
professional to monitor the changing 
field in sufficient detail and apply 
their professional skills. That is why a 
body is needed to prepare and mo-
nitor the effectiveness and efficiency 
of genetic tests used in Finland’s 
healthcare system. The guidelines 
must take into account internatio-
nal recommendations, international 
developments in the field and the 
availability of services, particularly 
in other EU countries. This expert 
role would be a natural fit for the 
national genome centre. 
ACTIVITY 11 
– Promote the use of genetic 
risk profiling in the prevention 
of diseases 
As genomic data becomes more 
precise, it will be possible to identify 
susceptibility to disease better. That 
opens up new possibilities for the 
prevention of diseases. Guidelines 
and a databank will be created 
for service providers and health-
care professionals. It will be easy 
to retrieve information about gene 
research from the databank as well 
as information on how to make de-
cision based on the results and how 
the results can be used in practical 
work. Risk profile-based prevention 
could be based on medical treat-
ment and changes to lifestyle, and 
to be successful there would also 
be a need for support services for 
individuals.
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Practical applications of 
genomic data
Genetic information helps 
prevent sudden death 
A 56-year-old woman developed sudden 
chest pain which was found to be caused 
by a rupture of the ascending aorta. She 
survived after an emergency operation. 
Further examination of the family revealed 
that the risk of rupture of the aorta was 
inherited in a dominant pattern, and the 
underlying genetic defect was identified. 
All those at risk need to be monitored. 
During genetic counselling, genetic testing 
was performed on the patient’s four 
siblings. One of the siblings had the genetic 
defect, and therefore genetic counselling 
and testing of the children was necessary. 
The genetic defect was also identified 
in the patient’s son who already had an 
enlarged aortic root. An elective operation 
was carried out thus avoiding the risk 
of sudden death from a rupture of the 
aorta. Since three siblings did not have the 
genetic defect, they and their children did 
not need any follow-up. 
Practical applications of genomic data
From cardiovascular disease risk assessment to prevention 
using genomic data
Several thousand Finns unknowingly suffer from familial hypercholesterolaemia where 
cholesterol levels are very high due to an inherited genetic defect. Without treatment 
their risk of cardiovascular disease is several times higher than in the average popu-
lation. Their increased susceptibility could be easily detected with a genetic test and 
taken into account in lifestyle choices and medication from early childhood. 
The common variation in the genome of the population influences our risk to develop 
cardiovascular disease. Half of the difference in individual risk can be explained by 
inherited characteristics. Compared to the average Finn, almost a million Finns carry 
changes in their genome that double the risk of heart disease. 
In health promotion and prevention of cardiovascular events, there is a need for data 
on changes in the genome and their significance as well as for guidelines on how to 
apply genomic data in healthcare. The use of genomic data can reduce morbidity and 
mortality and lead to more cost-effective healthcare. 
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ACTIVITY 12 
– Provide healthcare 
professionals with a clinical 
decision-making support tool 
based on genomic data
Risk profiles for diseases are 
generated from a large number, 
usually several tens, of variations 
in genetic makeup which are 
combined with other information 
about the patient. This is possible 
with electronic decision-making 
support. These kinds of informa-
tion technology solutions have to 
be developed as tools to support 
healthcare professionals. The most 
effective solutions will be disco-
vered through pilot studies. 
ACTIVITY 13 
– Analyse the costs and benefits 
of making use of genomic data
Even though many kinds of gene-
tic tests are possible, the use of all 
of them is not necessarily cost- 
effective. On the other hand, it is 
possible to concentrate on effective 
treatments on the basis of gene-
tic tests and to avoid the costs of 
ineffective or harmful treatments. 
Not all tests are associated with 
possibilities for interventions that 
promote health or prevent diseases 
either. The cost-effectiveness of the 
use of genomic data will have to 
be assessed at a national level and 
monitored as part of the operations 
of the genome centre. 
Practical applications of 
genomic data
Genetic test enables targeted 
treatment of cancer
Genetic changes in cancerous lesions guide 
the development of cancer. Identification 
of these changes enables the targeted 
treatment of cancer.
In the example case, the patient had can-
cer of the colon removed by surgery, and 
he underwent chemotherapy because the 
cancer had spread to lymph nodes. After 
one year the patient was found with liver 
metastases which could not be surgically 
removed due to their size and number. 
In tests for KRAS and NRAS oncogenes, 
no mutations were found in the cancerous 
tissue, and targeted antibody treatment 
against EGFR was started. The response 
to treatment was positive and the patient 
was operated to remove the liver metasta-
ses. There was no recurrence of the cancer 
during follow-up. If a mutation would 
have been found in the KRAS or NRAS 
oncogenes, the treatment would have been 
ineffective or even harmful. 
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 3.6 INDIVIDUALS ARE ABLE TO 
MAKE USE OF GENOMIC DATA IN THEIR OWN LIVES
Currently genomic data is mainly used to diagnose diseases and to guide the selection of treatment. In the future, 
genetic risk profiling will be increasingly available as a preventive intervention or as part of a personal health plan. 
This opportunity together with the necessary support services must be equally available to all.
More and more Finns are interest-
ed in maintaining and promoting 
their health through lifestyle choices. 
Information about individual genetic 
makeups will be critical in the future 
when we assess lifestyle risks and 
make lifestyle choices. Healthcare 
needs common guidelines on the use 
of genome-wide tests. At the same 
time we must consider the availability 
of such tests from the perspective of 
those who want to know about their 
own genomic data. The provision of 
services must not lead to unequal 
treatment of patients. 
In Finland, genome-wide tests have 
not been availave to consumers. 
Some Finns have bought these 
services via the Internet from 
companies based abroad. In such 
cases, data about individuals’ genetic 
makeup cannot be used in domestic 
research or in the development of 
new services even after it has been 
anonymised. The data are also not 
stored as part of the Finnish genom-
ic database. 
Legislation must be developed so 
that people have the right to use 
their genetic information and decide 
on how it is used through consent 
management. The individual should 
also have the opportunity to acquire 
information about their genetic 
makeup and on the other hand, the 
right to share it with others. 
ACTIVITY 14 
– Provide guidelines for people 
on services related to genetic 
testing
A clear health service pathway and 
guidelines have to be developed for 
people on what types of genet-
ic or genomic tests are available 
and where. The pathway will also 
indicate which organisations offer 
interpretation of results, what tests 
can reveal and what advice related 
to the results is provided to sup-
port health planning. People must 
also be given reliable comparative 
data about services provided by 
the private and third sector that are 
aimed at consumers. The use of ser-
vices must always be voluntary and 
based on the individual’s desire to 
know. Resources should be directed 
towards solutions that promote the 
nation’s health. These kinds of appli-
cations are particularly associated 
with disease risk profiling, evalua-
tion of the suitability of drugs and 
the prevention of disease through 
lifestyles that promote health. 
It should be ensured that people 
receive up-to-date and reliable infor-
mation about using genomic data in 
promoting their own health. 
ACTIVITY 15 
– Provide individuals with 
access to genomic data tools
Provide people with general guide-
lines on the use of genomic data 
in promoting health and create 
related services to support decision 
making. Create a genome portal 
which would provide the public with 
information about genetics as well 
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as online tools to utilise informa-
tion about their genetic makeup. In 
addition, investigate the opportuni-
ties to provide people with virtual 
health services related to the use of 
genomic data on an experimental 
basis. This could be achieved, for 
example as a virtual clinic service by 
combining the individual’s consent 
with his or her wellbeing, patient 
and genetic information. 
ACTIVITY 16 
– Build in secondary education 
the capability to use genomic 
data
Develop secondary education cur-
ricula to build students’ capability to 
apply genomic information to make 
informed decisions about their own 
health. Teaching about genomic data 
would be a natural part of health 
education for example.
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3.7 FINLAND IS AN INTERNATIONALLY ATTRACTIVE RESEARCH 
AND BUSINESS ENVIRONMENT IN THE FIELD OF GENOMICS
Finland has invested a considerable amount of public funds in health-related research. As a result we have become 
one of the leading countries in science, including in genetics research. However, society has not been able to fully 
benefit from research investment, nor has the investment sufficiently generated economic activity or produced 
enough added value. There are significant opportunities for business, commercial growth and employment espe-
cially in the development of drugs and in digital healthcare research.
Finland has a strong tradition of 
genetic research, comprehensive 
health databases and high-quality 
sample collections in biobanks. All 
of this combined with genomic data 
amounts to a considerable nation-
al capital which is of interest to 
international research and investors. 
Investments are needed to promote 
genomics research and development 
in the field. The results of such re-
search and innovation activities are 
of direct benefit to Finns and the 
Finnish healthcare system.
In Finland, the law governing bio-
banks already allows cooperation 
in research between the public 
sector and companies. Biobanks are 
allowed to deliver samples and their 
data to companies for research and 
development projects. However, the 
objective is not to pass the sam-
ples to research organisations and 
companies, but to generate knowl-
edge. This will enable targeted and 
individualised study designs which 
are essential for drug development. 
A national service point, the ge-
nome centre, is needed for research 
organisations and companies inter-
ested in cooperation. The role of 
the centre is to provide centralised 
services for research projects and 
agreements. It must have the au-
thority to make contracts on behalf 
of the Finnish cooperation net-
work. The service point could also 
function as the national coordinating 
body for international cooperation 
projects.
In the case of health technology 
solutions, the development of a 
product typically takes years before 
it is ready for the market. That is 
why funding is a bottleneck for many 
small companies. In particular, start-
up businesses with international 
aspirations need long-term funding. 
Finland’s risk and capital investment 
markets should be further devel-
oped to support the growth and 
internationalisation of companies. 
Tekes is one organisation that has 
reacted to the situation by creating 
a new funding instrument in 2014 to 
amend shortcomings in early-stage 
funding for companies.
The national Health Sector Growth 
Strategy for Research and Innova-
tion Activities was completed in the 
spring of 2014. It defines the essen-
tial measures needed in order for 
Finnish health sector to be interna-
tionally successful. The objectives will 
be reached only by bringing togeth-
er the fragmented field of actors to 
cooperate, and through seamless 
cooperation between the public and 
private sectors. These are also the 
preconditions for Finland to become 
an interesting partner in genomics 
research and commercial activity in 
the genomics sector. 
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ACTIVITY 17 
– Establish a national service 
point that offers companies 
and research organisations 
centralised services related to 
research, agreement and com-
mercialization matters 
From the point of view of com-
panies, an actor the size of Finland 
must be able to provide a broad 
range of services from a national 
service point. Research organisations 
would also benefit from a central-
ised legal service with experience in 
drafting research agreements that 
are aligned with Finnish legislation. 
An entity providing a single point 
of contact would also function as a 
coordinating body for international 
cooperation projects.
ACTIVITY 18 
– Develop a national operating 
model for cooperation 
between the public and private 
sector that enables utilisation 
of genomic data, and the health 
data linked to it, in research 
and product development 
projects
Develop common operating 
principles and procedures to be 
followed in Finnish genome research. 
In this way, partners will not have to 
negotiate the models of coopera-
tion agreements with every service 
provider and research group sepa-
rately. The operating model must be 
flexible, and the authorization and 
ethical evaluation processes should 
be streamlined.
ACTIVITY 19 
– Provide access to genomic 
data and health information 
compiled from the data sources 
of various organisations for use 
in research and development 
activities
From the perspective of many inter-
national companies, Finnish organi-
sations are small players. Combining 
genomic and other health data 
produced by various organisations 
in the same database would also be 
in those organisations’ best interests. 
It would enable research across a 
broader range of areas than any 
organisation would be able to carry 
out alone. 
ACTIVITY 20 
– Establish a funding, producti-
sation and commercialisation 
programme 
In order to strengthen Finnish 
competitiveness in the international 
market and to support innovation 
in healthcare, there is a need to set 
up a programme for the develop-
ment of funding instruments and 
for building productisation skills. 
The objective is to speed up and 
facilitate the introduction of innova-
tions to international markets. The 
programme would not concentrate 
solely on genomic applications, but 
the significant role of genomics 
should be taken into account in the 
programme. 
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4.  ROADMAP FOR IMPLEMENTATION 
AND MONITORING
Genomic and other health data must be put to effective use, avoiding fragmentation in data management. There 
is a clear need to set up a body to coordinate activities at the national level and to provide research institutes, 
healthcare organisations and companies a single point of contact for services relating to genomic data. 
We need a genome centre. Its role 
would be to oversee the implemen-
tation of the genome strategy, serve 
as a single point of contact for stake-
holders needing research, contractual 
and commercialisation services, and 
develop a national reference data-
base of genomes. Other responsi-
bilities of the genome centre would 
include: standardize and streamline 
the ethical evaluation of research 
projects, promote networking and 
collaboration of various actors in the 
sector, and facilitate Finland’s partic-
ipation in international collaborative 
projects. The genome centre should 
enable the storage of genomic data, 
data integration and interfacing with 
other services such as biobanks, 
healthcare systems, research data 
and reference materials as well as 
ethical review committees. It will take 
several years to build and develop 
the genomic data services. New 
opportunities will be created around 
the genomic data services with the 
potential to generate new business, 
new professions and an entire eco-
system. 
RESPONSIBILITIES OF 
THE GENOME CENTRE 
(to be elaborated on during strategy 
implementation) 
• Develop a national reference 
database of genomes and a 
database of genomic variants
• Serve as a single point of con-
tact for research, contractual 
and commercialisation services
• Evaluate at the national level 
the validity and utility of genetic 
tests
• Promote ethical practices in the 
use of genomic data
• Standardize and streamline 
ethical evaluation of research 
projects 
• Promote networking and col-
laboration between the various 
actors in the sector
• Initiate and stimulate public 
debate on the utilisation of 
genomic data
• Facilitate Finland’s participation 
in international collaborative 
projects
The working group recommends 
that the genome centre be a per-
manent body governed by law and 
that national funding be secured 
for it (possibly a dedicated budget 
line in the government budget). The 
drafting of legislation regarding the 
genome centre should start imme-
diately. 
While the legislation is being pre-
pared, other activities proposed in 
this strategy can be carried out with 
a view to achieving the set goals by 
2020. A tentative implementation 
schedule is provided in the roadmap 
below (Figure 4). A working group 
should be set up to plan the estab-
lishment of the genome centre. 
The estimated costs of implement-
ing the genome strategy by 2020 
are EUR 50 million. Most of this 
funding is required for establishing 
the genome centre. The centre will 
need between 15 and 20 employees 
including 10 to 15 high-level experts. 
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2015 2016 2017 2018 2019 2020
Legislation regarding the genome centre prepared
Legal and ethical framework developed
Genomics research closely integrated 
into healthcare
Healthcare personnel have the skills 
to use genomic data
Information systems enable the effective use of 
genomic data
Genomic data are widely used in healthcare
Individuals are able to make use of genomic 
data in their own lives
Finland is an internationally attractive research and 
business environment in the field of genomics
ACTIVITY 0 Establishment of genome centre
ACTIVITY 1   Confirm ethical principles
ACTIVITY 4  Create conditions for applying genomic data
ACTIVITY 5  Reinforce and update genetics education 
ACTIVITY 3  Create national reference database of genomes
ACTIVITY 2  Prepare legal framework
ACTIVITY 6  Develop and implement continuing education programme
ACTIVITY 7  Assess need for professionals in clinical genetics
 
ACTIVITY 8  Develop IT architecture for genomic data
ACTIVITY 10  Develop procedure for evaluation of genetic tests
ACTIVITY 11  Promote use of genetic risk profiling
ACTIVITY 9  Ensure genetic testing is performed on patients and relatives
ACTIVITY 13  Analyse costs and benefits of genomic data 
ACTIVITY 14  Provide guidelines for people on testing services
ACTIVITY 12  Provide clinical decision-making support tool
ACTIVITY 15  Provide individuals with access to genomic data tools
ACTIVITY 18  Develop cooperation model
ACTIVITY 19  Provide access to data for use in R&D
ACTIVITY 20  Establish funding, productisation and commercialisation programme
ACTIVITY 16  Build in secondary education the capability to use genomic data
ACTIVITY 17  Establish national service point
Figure 4. Proposed roadmap for the implementation of the genome strategy.
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USEFUL LINKS
American Society of Human Genetics http://www.ashg.org
British Society for Genetic Medicine http://www.bsgm.org.uk
Center for Genetics and Society http://www.geneticsandsociety.org
Council of Europe http://www.coe.int/t/dg3/healthbioethic/default_en.asp
European Alliance for Personalised Medicine http://euapm.eu
European Society of Human Genetics http://www.bsgm.org.uk
Genomics England http://www.genomicsengland.co.uk
Global Alliance for Genomics and Health http://genomicsandhealth.org
Human Genome Organisation (HUGO) http://www.hugo-international.org
Human Genome Variation Society http://www.hgvs.org
HumGen International Database 
on the Legal and Socio-Ethical Aspects of 
Population Genomics http://www.dtcgenetest.org
International Genetic Epidemiology Society http://www.geneticepi.org
Nuffield Council on Bioethics http://nuffieldbioethics.org
OECD www.oecd.org/sti/biotechnology/genomics
Public Health Genomics European Network http://www.phgen.eu/typo3/index.php
World Health Organization http://www.who.int/topics/genomics/en
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APPENDIX 2
GENOME STRATEGY WORKING 
GROUP MEMBERSHIP 
CHAIR:
Liisa-Maria Voipio-Pulkki, Director, Ministry of Social Affairs and Health
VICE-CHAIR:
Kristiina Aittomäki, Professor, Chief Physician, University of Helsinki and HUSLAB, 
Hospital District of Helsinki and Uusimaa
MEMBERS:
Jaakko Yrjö-Koskinen, Ministerial Counsellor, Ministry of Social Affairs and Health
Pia-Liisa Heiliö, Ministerial Adviser, Ministry of Social Affairs and Health
Jari Porrasmaa, Senior Adviser, Ministry of Social Affairs and Health
Anneli Törrönen, Ministerial Adviser, Ministry of Social Affairs and Health (until 1 December 2014)
Sandra Liede, Senior Officer, Legal Affairs, National Supervisory Authority for Welfare and Health (Valvira)
Aarno Palotie, Professor, 
Institute for Molecular Medicine Finland (FIMM), University of Helsinki 
and The Broad Institute of MIT and Harvard, Boston, USA
Ari Ristimäki, Professor, Department Head, University of Helsinki and HUSLAB, Hospital District of Helsinki and Uusimaa
Tuula Tiihonen, Senior Lead, Finnish Innovation Fund Sitra
IN ADDITION, THE FOLLOWING PERSONS PARTICIPATED TO THE MEETINGS 
OF THE WORKING GROUP AND TO THE FORMULATION OF THE NATIONAL STRATEGY:
Antti Kivelä, Director, Finnish Innovation Fund Sitra
Lauri Salmivalli, Health Care & Life Science Industry Leader, Deloitte Finland
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